Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Desipramine
Drug ID BADD_D00612
Description Desipramine hydrochloride is a dibenzazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, desipramine does not affect mood or arousal, but may cause sedation. In depressed individuals, desipramine exerts a positive effect on mood. TCAs are potent inhibitors of serotonin and norepinephrine reuptake. Secondary amine TCAs, such as desipramine and nortriptyline, are more potent inhibitors of norepinephrine reuptake than tertiary amine TCAs, such as amitriptyline and doxepine. TCAs also down-regulate cerebral cortical β-adrenergic receptors and sensitize post-synaptic serotonergic receptors with chronic use. The antidepressant effects of TCAs are thought to be due to an overall increase in serotonergic neurotransmission. TCAs also block histamine-H1 receptors, α1-adrenergic receptors and muscarinic receptors, which accounts for their sedative, hypotensive and anticholinergic effects (e.g. blurred vision, dry mouth, constipation, urinary retention), respectively. See toxicity section below for a complete listing of side effects. Desipramine exerts less anticholinergic and sedative side effects compared to tertiary amine TCAs, such as amitriptyline and clomipramine. Desipramine may be used to treat depression, neuropathic pain (unlabeled use), agitation and insomnia (unlabeled use) and attention-deficit hyperactivity disorder (unlabeled use).
Indications and Usage For relief of symptoms in various depressive syndromes, especially endogenous depression. It has also been used to manage chronic peripheral neuropathic pain, as a second line agent for the management of anxiety disorders (e.g. panic disorder, generalized anxiety disorder), and as a second or third line agent in the ADHD management.
Marketing Status approved; investigational
ATC Code N06AA01
DrugBank ID DB01151
KEGG ID D07791
MeSH ID D003891
PubChem ID 2995
TTD Drug ID D01UTL
NDC Product Code 69238-1053; 69238-1063; 69238-1061; 71335-0208; 69238-1055; 69238-1057; 69238-1059
UNII TG537D343B
Synonyms Desipramine | Desmethylimipramine | Demethylimipramine | Desipramine Hydrochloride | Hydrochloride, Desipramine | Norpramin | Ratio-Desipramine | Ratio Desipramine | Nu-Desipramine | Nu Desipramine | Pertofrane | Pertrofran | Pertofran | Petylyl | PMS-Desipramine | PMS Desipramine | Apo-Desipramine | Apo Desipramine | Novo-Desipramine | Novo Desipramine
Chemical Information
Molecular Formula C18H22N2
CAS Registry Number 50-47-5
SMILES CNCCCN1C2=CC=CC=C2CCC3=CC=CC=C31
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Acute coronary syndrome02.02.02.015; 24.04.04.011--Not Available
Inappropriate antidiuretic hormone secretion14.05.07.001; 05.03.03.001--Not Available
Disturbance in sexual arousal19.08.04.003--Not Available
Blood alkaline phosphatase increased13.04.02.004--
Mantle cell lymphoma16.28.05.001; 01.15.05.0010.007437%Not Available
Decreased appetite14.03.01.005; 08.01.09.028--
Erectile dysfunction21.03.01.007; 19.08.04.001--
Ill-defined disorder08.01.03.049--Not Available
Disease progression08.01.03.0380.007437%
Pancreatic enzymes increased13.05.01.004--Not Available
Psychotic disorder19.03.01.002--
Unevaluable event08.01.03.0510.010908%Not Available
Bone marrow failure01.03.03.005--
Painful ejaculation21.03.01.014; 19.08.05.007--Not Available
Liver function test increased13.03.04.031--Not Available
Cross sensitivity reaction10.01.01.036--Not Available
The 5th Page    First    Pre   5    Total 5 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene